MedTrace Logo

Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

NCT03919500 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1285

Last updated 2019-04-19

No results posted yet for this study

Summary

This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants. Half of participants will receive EPO, while the other half will receive a placebo.

Conditions

  • Premature Infant

Interventions

DRUG

EPO

Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.

DRUG

Normal saline

Infants in control group are administered normal saline with the same volume and period as EPO.

Sponsors & Collaborators

  • Zhengzhou Children's Hospital, China

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Women and Children Health Care Center of Luoyang, China

    collaborator UNKNOWN

  • Göteborg University

    collaborator OTHER

  • Zhengzhou University

    lead OTHER

Principal Investigators

  • Changlian Zhu, PhD · Third Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
72 Hours
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03919500 on ClinicalTrials.gov